Page last updated: 2024-12-08

formycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID447199
CHEMBL ID471524
CHEBI ID42452
SCHEMBL ID980049
MeSH IDM0106455

Synonyms (29)

Synonym
d-ribitol, 1-c-(7-amino-1h-pyrazolo(4,3-d)pyrimidin-3-yl)- 1,4-anhydro-, (s)-
8-aza-9-deazaadenosine
nsc 102811
brn 0624229
1h-pyrazolo(4,3-d)pyrimidine, 7-amino-3-beta-d-ribofuranosyl-
d-ribitol, 1-c-(7-amino-1h-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-, (s)-
7-amino-3-beta-d-ribofuranosyl-1h-pyrazolo(4,3-d)pyrimidine
(2s,3r,4s,5r)-2-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
formycin
d-ribitol, 1-c-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-,(1s)-
6742-12-7
formycin a
FMC ,
(1s)-1-(7-amino-1h-pyrazolo[4,3-d]pyrimidin-3-yl)-1,4-anhydro-d-ribitol
DB02281
1NC3
CHEBI:42452 ,
2QTT
(2s,3r,4s,5r)-2-(7-amino-2h-pyrazolo[4,3-d]pyrimidin-3-yl)-5-(hydroxymethyl)oxolane-3,4-diol
CHEMBL471524
KBHMEHLJSZMEMI-KSYZLYKTSA-N
SCHEMBL980049
HY-102026
Q27120468
CS-0022666
MS-23775
GLXC-25323
DTXSID20863937
AKOS040733185

Research Excerpts

Overview

Formycin A is a potent purine nucleoside antibiotic with a C-glycosidic linkage between the ribosyl moiety and the pyrazolopyrimidine base.

ExcerptReferenceRelevance
"Formycin A is a potent purine nucleoside antibiotic with a C-glycosidic linkage between the ribosyl moiety and the pyrazolopyrimidine base. "( Identification of the Formycin A Biosynthetic Gene Cluster from Streptomyces kaniharaensis Illustrates the Interplay between Biological Pyrazolopyrimidine Formation and de Novo Purine Biosynthesis.
Geng, Y; Irani, S; Ko, Y; Liu, HW; Ogasawara, Y; Ren, D; Wang, SA; Zeng, J; Zhang, Y, 2019
)
2.27

Compound-Compound Interactions

Formycin A (FoA) (20 mg/kg), combined with nitrobenzyl mercaptopurine ribonucleoside 5'-monophosphate (NBMPR-P) (10mg/kg) was effective in reducing the size of the foot pad lesions from 7 to 7.

ExcerptReferenceRelevance
"The toxicology and pharmacology of formycin both as a single agent and combined with the adenosine deaminase inhibitor 2'-deoxycoformycin (dCF) were examined in outbred Swiss mice heterozygous for the nude gene (nu/+)."( Biochemical pharmacology and toxicology of formycin alone and in combination with 2'-deoxycoformycin (pentostatin).
Calabresi, P; Chu, SH; Crabtree, GW; Dexter, DL; Diamond, I; Farineau, DM; Ghoda, LY; McGowan, DL; Parks, RE; Spremulli, EN, 1983
)
0.81

Bioavailability

ExcerptReferenceRelevance
" The described method has been successfully applied to the quantitative determination of formycin A in plasma and should be useful for clinical and bioavailability investigations."( High-performance liquid chromatographic assay of formycin A in plasma after solid-phase extraction.
Jagiełło-Wójtowicz, E; Misztal, G; Paw, B; Skierski, JS, 1999
)
0.78

Dosage Studied

ExcerptRelevanceReference
" With this latter dosage or with 104 mg/kg/day there was no acute toxicity of formycin B to bone marrow or formed elements of the blood."( Leishmania donovani: oral efficacy and toxicity of formycin B in the infected hamster.
Berman, JD; Hanson, WL; Keenan, CM; Lamb, SR; Waits, VB, 1983
)
0.75
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
formycin
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MTA/SAH nucleosidaseEscherichia coliKi10.00000.75005.375010.0000AID977610
Chain B, MTA/SAH nucleosidaseEscherichia coliKi10.00000.75005.375010.0000AID977610
Chain A, MTA/SAH nucleosidaseEscherichia coliKi10.00000.75005.375010.0000AID977610
Chain B, MTA/SAH nucleosidaseEscherichia coliKi10.00000.75005.375010.0000AID977610
Chain A, 5'-methylthioadenosine nucleosidaseArabidopsis thaliana (thale cress)Ki48.00008.300028.150048.0000AID977610
Chain B, 5'-methylthioadenosine nucleosidaseArabidopsis thaliana (thale cress)Ki48.00008.300028.150048.0000AID977610
Chain A, 5'-methylthioadenosine nucleosidaseArabidopsis thaliana (thale cress)Ki48.00008.300028.150048.0000AID977610
Chain B, 5'-methylthioadenosine nucleosidaseArabidopsis thaliana (thale cress)Ki48.00008.300028.150048.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
adenosine catabolic processAdenosine deaminase Bos taurus (cattle)
cell adhesionAdenosine deaminase Bos taurus (cattle)
nucleotide metabolic processAdenosine deaminase Bos taurus (cattle)
purine ribonucleoside monophosphate biosynthetic processAdenosine deaminase Bos taurus (cattle)
inosine biosynthetic processAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
adenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
protein bindingAdenosine deaminase Bos taurus (cattle)
zinc ion bindingAdenosine deaminase Bos taurus (cattle)
2'-deoxyadenosine deaminase activityAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
lysosomeAdenosine deaminase Bos taurus (cattle)
cytoplasmic vesicle lumenAdenosine deaminase Bos taurus (cattle)
anchoring junctionAdenosine deaminase Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID108456Minimum inhibitory concentration required to reduce measles virus induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID54506Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID202931Compound evaluated for the inhibitory concentration of S49 Mouse Lymphoma T-cells1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Improved synthesis of 2'-deoxyformycin A and studies of its in vitro activity against mouse lymphoma of T-cell origin.
AID199875Virus rating against rhinovirus type 1A1989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Analysis of the in vitro antiviral activity of certain ribonucleosides against parainfluenza virus using a novel computer aided receptor modeling procedure.
AID229570Ratio of kinetic parameters Vmax to the of Km; Vmax/Km1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity.
AID1136399Activity of human erythrocyte purine nucleoside phosphorylase assessed as ribose relase at 5 umol after 30 mins by orcinol reaction relative to guanosine1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Stereoelectronic factors in the binding of substrate analogues and inhibitors to purine nucleoside phosphorylase isolated from human erythrocytes.
AID54505Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells coxsackie virus type 41984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID155599Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells parainfluenza virus type 31984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID204956Minimum inhibitory concentration required to reduce sindbis virus induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID199168Minimum inhibitory concentration required to reduce reo virus type 1 induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID1878799Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in dog MDCK cells assessed as reduction in viral titer in supernatants incubated for 24 hrs by plaque assay2022Bioorganic & medicinal chemistry, 03-01, Volume: 57Synthesis and antiviral activity of formycin derivatives with anti-influenza virus activity.
AID96612Minimum inhibitory concentration required to reduce incorporation of [5-3H]-Urd into TCA-insoluble material from murine leukemia L1210 cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID96613Minimum inhibitory concentration required to reduce incorporation of [methyl-3H]dThd into TCA-insoluble material from murine leukemia L1210 cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID216128Concentration that produced 50% inhibition of WIL2 leukemia tumor cell growth was determined1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and antitumor activity of certain 3-beta-D-ribofuranosyl-1,2,4-triazolo[3,4-f]-1,2,4-triazines related to formycin prepared via ring closure of a 1,2,4-triazine precursor.
AID34142Virus rating against adenovirus type 21989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Analysis of the in vitro antiviral activity of certain ribonucleosides against parainfluenza virus using a novel computer aided receptor modeling procedure.
AID84611Minimum inhibitory concentration required to reduce Herpes simplex virus type 2 (HSV-2 strain G) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID83887Compound was tested for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID217478Minimum inhibitory concentration required to reduce Vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID162252Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells polio virus type 11984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID96649Concentration that produced 50% inhibition of L1210 leukemia tumor cell growth was determined1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and antitumor activity of certain 3-beta-D-ribofuranosyl-1,2,4-triazolo[3,4-f]-1,2,4-triazines related to formycin prepared via ring closure of a 1,2,4-triazine precursor.
AID162251Minimum inhibitory concentration required to reduce Polio virus type 1 induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID87798Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Hela cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID204960Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells sindbis virus1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID155586Minimum inhibitory concentration required to reduce parainfluenza type 3 induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID87045Virus rating of against herpes simplex virus type 21989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Analysis of the in vitro antiviral activity of certain ribonucleosides against parainfluenza virus using a novel computer aided receptor modeling procedure.
AID85570Minimum inhibitory concentration required to reduce Herpes simplex virus type 1 (HSV-1, strain KOS) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID217479Minimum inhibitory concentration required to reduce vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID96611Minimum inhibitory concentration required to reduce incorporation of [4,5-3H]leucine into TCA-insoluble material from murine leukemia L1210 cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID108463Compound was tested for antiviral activity against measles virus in vero cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID33817Kinetic parameter was determined against calf intestine adenosine deaminase expressed as Km1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity.
AID96608Inhibition of murine leukemia L1210 cell growth1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID216544Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells vesicular stomatitis virus (VSV)1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID33839Kinetic parameter was determined against calf intestine adenosine deaminase expressed as Vmax1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity.
AID1878800Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter96 Aqueous one solution assay2022Bioorganic & medicinal chemistry, 03-01, Volume: 57Synthesis and antiviral activity of formycin derivatives with anti-influenza virus activity.
AID43841Concentration that produced 50% inhibition of CCRF-CEM leukemia tumor cell growth was determined1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and antitumor activity of certain 3-beta-D-ribofuranosyl-1,2,4-triazolo[3,4-f]-1,2,4-triazines related to formycin prepared via ring closure of a 1,2,4-triazine precursor.
AID202930Compound along with 10 uM of erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) was tested against mouse lymphoma T-cells1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Improved synthesis of 2'-deoxyformycin A and studies of its in vitro activity against mouse lymphoma of T-cell origin.
AID54507Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells coxsackie virus type B41984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID217996Compound was tested for antiviral activity against vaccinia virus in primary rabbit kidney cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID218065Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Vero cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID167151Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in primary rabbit kidney cells1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID217836Minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50%1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID199175Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells reovirus type 11984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID228915Coronary vasoactivity as molar potency ratio (MPR), the quotient of ED50 of adenosine by that of the test nucleoside1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID84957Compound was tested for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID216409Compound was tested for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cells1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID155596Virus rating against parainfluenza virus type 31989Journal of medicinal chemistry, Apr, Volume: 32, Issue:4
Analysis of the in vitro antiviral activity of certain ribonucleosides against parainfluenza virus using a novel computer aided receptor modeling procedure.
AID98562Cytotoxic concentration required to reduce rate of L1210 cell proliferation after 48 hr1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
2-Fluoroformycin and 2-aminoformycin. Synthesis and biological activity.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2008Journal of molecular biology, Apr-18, Volume: 378, Issue:1
Molecular determinants of substrate specificity in plant 5'-methylthioadenosine nucleosidases.
AID1811Experimentally measured binding affinity data derived from PDB2003The Journal of biological chemistry, Mar-07, Volume: 278, Issue:10
Structure of Escherichia coli 5'-methylthioadenosine/ S-adenosylhomocysteine nucleosidase inhibitor complexes provide insight into the conformational changes required for substrate binding and catalysis.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2003The Journal of biological chemistry, Mar-07, Volume: 278, Issue:10
Structure of Escherichia coli 5'-methylthioadenosine/ S-adenosylhomocysteine nucleosidase inhibitor complexes provide insight into the conformational changes required for substrate binding and catalysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (37.97)18.7374
1990's20 (25.32)18.2507
2000's15 (18.99)29.6817
2010's13 (16.46)24.3611
2020's1 (1.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.77 (24.57)
Research Supply Index4.39 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index50.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other79 (98.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]